Junning Lee
CIK 1596187 · Sr. VP, Technical Operations · last filed 2017-02-22
Junning Lee is a Sr. VP, Technical Operations who has filed 18 SEC Form 4 insider transactions across 2 companies since 2014. The most recent filing shows the insider had shares withheld for taxes covering $324.7K of TBPH on Feb 22, 2017. Across all open-market trades the lifetime net is −$1.1M, making them a net seller over the disclosed history. 9 SEC filings were submitted jointly with Innoviva, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
THRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) Delisted | Sr. VP, Technical Operations | 234,071 | $17.03 | $3.99M | $116.1K | 14 | 2017-02-22 |
| Innoviva, Inc. (THRX) Delisted | Sr. VP, Technical Operations | 262,198 | $4.06 | $1.06M | -$1.20M | 4 | 2014-08-22 |
Recent Filings
18 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-02-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −9,611 | -$324.7K | EDGAR |
| 2016-11-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −3,785 | -$121.0K | EDGAR |
| 2016-08-23 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −3,785 | -$105.6K | EDGAR |
| 2016-05-24 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −3,785 | -$77.8K | EDGAR |
| 2016-03-17 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +90,000 | $0 | EDGAR |
| 2016-02-23 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −16,049 | -$251.2K | EDGAR |
| 2015-11-24 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −1,037 | -$17.8K | EDGAR |
| 2015-08-18 | Theravance Biopharma, Inc. (TBPH) Delisted | Buy (P) | +9,000 | $116.1K | EDGAR |
| 2015-06-04 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −5,152 | -$71.3K | EDGAR |
| 2015-05-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −748 | -$10.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.